Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
33 results
  • Cervical Cancer, Kidney Cancer, Lung Cancer, Breast Cancer, Bladder Cancer, Head and Neck Cancer

25-855          Phase II

A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, a Nectin4/Trop2 ADC, as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors

  • Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Ovarian Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Cervical Cancer, Head and Neck Cancer, Breast Cancer, Gastric (Stomach) Cancer, Metastatic/Advanced Cancer

25-075          Phase II

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

  • Bladder Cancer, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Cancer, Prostate Cancer, Esophageal Cancer, Lung Cancer

24-353          Phase I

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

  • Breast Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer

26-124          Phase I

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors

  • Colorectal Cancer, Lung Cancer, Breast Cancer

24-514          Phase I

A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)

  • Breast Cancer

25-016          Phase II

A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)

  • Breast Cancer

19-578          Phase II

A Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer (NeoSTAR)

  • Brain Tumors, Breast Cancer

24-575          Phase I

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM16390 in Patients with Advanced or Metastatic Solid Tumors

  • Breast Cancer, Endometrial Cancer, Liver Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer

25-587          Phase II

A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors

Showing 1 - 10 of 33 results